Research Analysts’ Weekly Ratings Updates for Immunocore (IMCR)

Immunocore (NASDAQ: IMCR) has recently received a number of price target changes and ratings updates:

• 11/10/2025 – Immunocore had its price target raised by analysts at Morgan Stanley from $34.00 to $36.00. They now have an “equal weight” rating on the stock.
• 11/8/2025 – Immunocore was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 10/31/2025 – Immunocore is now covered by analysts at Wells Fargo & Company. They set an “overweight” rating and a $60.00 price target on the stock.
• 10/31/2025 – Immunocore is now covered by analysts at Wells Fargo & Company. They set an “overweight” rating and a $60.00 price target on the stock.
• 10/22/2025 – Immunocore had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
• 10/8/2025 – Immunocore had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 9/27/2025 – Immunocore had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 9/18/2025 – Immunocore is now covered by analysts at Guggenheim. They set a “neutral” rating on the stock.

Insiders Place Their Bets

In other news, insider David M. Berman sold 22,532 shares of the company’s stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $35.67, for a total transaction of $803,716.44. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 10.40% of the stock is currently owned by corporate insiders.

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.